Literature DB >> 25391828

Sudden death in a patient with bone marrow transplant by a fungus among us.

Lemuel Non1, Joanna Paula Sta Cruz2, Sherilyn Tuazon3.   

Abstract

Mucormycosis is rare, presenting as breakthrough infection among haematological and transplant patients on prophylaxis with voriconazole. We report an unusual presentation of this infection, that which is pneumonia progressing to cardiac arrest. A 68-year-old woman with refractory acute myelogenous leukaemia on voriconazole prophylaxis was initially admitted for neutropenic fever and pneumonia. She was discharged improved on antibiotics and voriconazole for presumed aspergillosis. She returned after 1 month with the same presentation. She eventually improved on antibiotics and voriconazole, and eventually received bone marrow transplantation. Three days later, she developed pleuritic chest pain, dyspnoea, and hypoxia requiring intubation. An hour after intubation, the patient arrested and expired. Autopsy revealed Rhizopus pneumonitis with pulmonary infarction, and emboli to her cerebellum, heart, thyroid and kidney. Mucormycosis is an emerging, fatal infection that should be suspected in haematological and transplant patients who deteriorate on voriconazole. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 25391828      PMCID: PMC4244385          DOI: 10.1136/bcr-2014-207403

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Authors:  Kieren A Marr; Rachel A Carter; Fulvio Crippa; Anna Wald; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2002-02-26       Impact factor: 9.079

2.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.

Authors:  Francisco M Marty; Lisa A Cosimi; Lindsey R Baden
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

3.  Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.

Authors:  Stéphane Vigouroux; Odile Morin; Philippe Moreau; Françoise Méchinaud; Nadine Morineau; Béatrice Mahé; Patrice Chevallier; Thierry Guillaume; Viviane Dubruille; Jean-Luc Harousseau; Noël Milpied
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

4.  How does antifungal pharmacology differ for mucormycosis versus aspergillosis?

Authors:  Russell E Lewis; Olivier Lortholary; Brad Spellberg; Emmanuel Roilides; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

5.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

Authors:  Dimitrios P Kontoyiannis; Michail S Lionakis; Russell E Lewis; Georgios Chamilos; Mimi Healy; Cheryl Perego; Amar Safdar; Hagop Kantarjian; Richard Champlin; Thomas J Walsh; Issam I Raad
Journal:  J Infect Dis       Date:  2005-03-16       Impact factor: 5.226

Review 6.  Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Infect Dis Clin North Am       Date:  2006-09       Impact factor: 5.982

Review 7.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

8.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.

Authors:  John R Wingard; Shelly L Carter; Thomas J Walsh; Joanne Kurtzberg; Trudy N Small; Lindsey R Baden; Iris D Gersten; Adam M Mendizabal; Helen L Leather; Dennis L Confer; Richard T Maziarz; Edward A Stadtmauer; Javier Bolaños-Meade; Janice Brown; John F Dipersio; Michael Boeckh; Kieren A Marr
Journal:  Blood       Date:  2010-09-08       Impact factor: 22.113

9.  Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis.

Authors:  Gregory A Lamaris; Ronen Ben-Ami; Russell E Lewis; Georgios Chamilos; George Samonis; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2009-05-01       Impact factor: 5.226

10.  Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis.

Authors:  Georgios Chamilos; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

View more
  1 in total

1.  Clinical presentations, diagnosis, management, and outcomes of renal mucormycosis: An overview of case reports.

Authors:  Mojtaba Didehdar; Zahra Chegini; Amin Khoshbayan; Alireza Moradabadi; Aref Shariati
Journal:  Front Med (Lausanne)       Date:  2022-08-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.